医疗综合性研究开发制造商Syngene International收购了其在美国的首家制造工厂-动脉网

Syngene Acquires its First Manufacturing Facility in the US

CISION 等信源发布 2025-03-11 03:02



可切换为仅中文







Expected to enhance global innovator flexibility with biologics drug substance facility in

预计通过生物药物质设施提高全球创新者的灵活性

Baltimore

巴尔的摩

BANGALORE, India

印度班加罗尔

，

March 10, 2025

2025年3月10日

/PRNewswire/ -- Syngene International Limited ('Syngene'), a global contract research, development, and manufacturing organization (CRDMO), today announced the acquisition of its first biologics site in the

/PRNewswire/ -- 全球合同研究、开发和制造组织（CRDMO）Syngene International Limited（“Syngene”）今天宣布收购其首个生物制品基地。

USA

美国

– fitted with multiple monoclonal antibody (mAbs) manufacturing lines.

– 配备多条单克隆抗体（mAbs）生产线。

继续阅读

Syngene's Newly Acquired Site in Baltimore, US. (PRNewsfoto/Syngene)

Syngene在美国巴尔的摩新收购的场地。（PRNewsfoto/Syngene）

The state-of-the-art biologics facility, acquired by Syngene

最先进的生物制品设施，由Syngene收购

USA

美国

Inc., a wholly owned subsidiary of Syngene, from Emergent Manufacturing Operations Baltimore, LLC (a subsidiary of Emergent BioSolutions Inc.), will expand Syngene's growing global biologics footprint to better serve its customers across both human and animal health market segments. The new site will increase Syngene's total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services.

Inc.是Syngene的全资子公司，从Emergent Manufacturing Operations Baltimore, LLC（Emergent BioSolutions Inc.的子公司）收购而来，这将扩大Syngene不断增长的全球生物制品业务版图，以更好地服务于其在人类和动物健康市场领域中的客户。新基地将使Syngene的总一次性生物反应器容量增加至50,000升，用于大分子的发现、开发和制造服务。

Additionally, it will provide Syngene's customers with continuity of supply from its four development and manufacturing facilities located in .

此外，它还将为 Syngene 的客户提供来自其四个开发和制造工厂的供应连续性。

India

印度

and

和

North America

北美

, offering services ranging from cell line development, process optimization and both clinical and commercial supply.

，提供从细胞系开发、工艺优化到临床和商业供应的服务。

Syngene's investment in its first facility in

Syngene 对其首个设施的投资在

the United States

美国

marks a strategic commitment to the US market, with significant benefits for the local economy and the broader life sciences industry. The facility is expected to create jobs, stimulate local economic activity, and strengthen domestic biologics manufacturing capabilities, while also contributing to pharmaceutical innovation and supply chain resilience.

标志着对美国市场的战略承诺，将为当地经济和更广泛的生命科学产业带来重大利益。该设施预计将创造就业机会、刺激当地经济活动、增强国内生物制品制造能力，同时还将推动药物创新并提升供应链韧性。

This investment highlights the potential for deeper economic collaboration between .

这项投资突显了双方更深层次经济合作的潜力。

India

印度

and

和

the United States

美国

, fostering sustained economic growth and advancing the shared goal of bolstering critical healthcare infrastructure.

，促进经济持续增长，并推动加强关键医疗基础设施的共同目标。

Peter Bains

彼得·贝恩斯

, CEO Designate, Syngene International Ltd., said,

“Syngene国际有限公司指定首席执行官表示，

'With one of the largest biologics R&D teams and commercial scale manufacturing capabilities in both

“拥有其中一个最大的生物制品研发团队和商业化规模的生产能力

India

印度

and the

和

USA

美国

, we now offer a compelling and flexible solution for global pharma and biotech customers. This investment will enable Syngene to cater to growing client requirements in an expanding market. It will also provide clients, access to collective service capability of multiple geographic sites, scientists and experience.'.

我们现在为全球制药和生物技术客户提供了一个引人注目且灵活的解决方案。这项投资将使Syngene能够满足不断增长的客户需求，并在不断扩大的市场中占据一席之地。同时，它还将为客户提供多个地理位置、科学家和经验的综合服务能力。

Alex Del Priore

亚历克斯·德尔·普里奥雷

, Senior Vice President – Development & Manufacturing Services, Syngene International Ltd., said,

，高级副总裁——开发与制造服务，Syngene国际有限公司，表示，

'This facility is a significant milestone for Syngene and comes in response to growing client demand in

“该设施是Syngene的一个重要里程碑，是对客户不断增长的需求的回应。

the United States

美国

, the fastest-growing biologics market. It strengthens our offering for animal health clients looking for USDA approval for their products. Most importantly, it increases the options we can offer our global customers, providing commercial-scale biologics manufacturing capabilities across our global network and will be underpinned by existing key client projects.'.

，增长最快的生物制品市场。它加强了我们为寻求美国农业部对其产品批准的动物健康客户提供的服务。最重要的是，它增加了我们可以提供给全球客户的选择，在我们的全球网络中提供商业规模的生物制品生产能力，并将由现有的关键客户项目提供支持。”

The investment will be synergistic with expected additional process development work that will be executed in

这项投资将与预计将在未来开展的额外工艺开发工作产生协同效应

India

印度

while manufacturing can be done in the US. The investment will be fully funded through internal accruals and cash. The Company will continue to maintain a robust balance sheet, a low debt profile, and a comfortable safety margin for debt covenants post this investment

虽然制造可以在美国进行。该投资将通过内部积累和现金全额资助。公司将继续保持稳健的资产负债表、较低的债务水平，并在此次投资后为债务契约保持舒适的安全边际。

。

As we ramp up utilization, we expect asset turnover to grow to 1x in less than 5 years, with EBIT margins expected to be in line with the Company average from FY30 and positively contribute to bottom line. The acquisition will not materially impact the current financial guidance given for fiscal year 2024 - 2025.

随着我们提高利用率，预计资产周转率将在不到5年内增长至1倍，而息税前利润率（EBIT margins）预计从2030财年起将与公司平均水平保持一致，并对净利润产生积极贡献。此次收购不会对2024-2025财年给出的当前财务指引产生重大影响。

In the short term, we expect minor dilution of operating margins as a result of costs to be incurred in this facility,.

短期内，由于此设施产生的成本，我们预计营业利润率将受到轻微稀释。

' added

' 已添加

Deepak Jain

迪帕克·贾恩

, CFO, Syngene International Ltd.

，首席财务官，Syngene国际有限公司。

Overall investment in the US facility is estimated to be around

美国工厂的总体投资估计在

US$50 million

5000万美元

, including the cost of acquisition (

，包括获取成本（

US$36.5 million

3650万美元

) and additional expenses to make the facility operational. The sale is expected to close in

）以及使设施投入运营的额外费用。预计此次出售将在

March 2025

2025年3月

, subject to the satisfaction of customary closing conditions. The upgraded

，视乎能否满足惯例的成交条件。升级后的

Baltimore

巴尔的摩

facility is strategically located near key biotech hubs in the Northeast of the US and will be available for client projects from second half of 2025. Syngene anticipates the site will see demand from innovative US mAb developers requiring direct access for 'onshore' production, as well as international innovators that want a US based manufacturing option and complements the capabilities and capacity available across its facilities in Bengaluru.

该设施战略位置靠近美国东北部的关键生物技术中心，将于 2025 年下半年开始承接客户项目。Syngene 预计，该基地将受到创新型美国单克隆抗体开发商的青睐，这些开发商需要“在岸”生产的直接访问权限；同时，希望拥有美国制造选项的国际创新者也将对其产生需求，这将与其位于班加罗尔的设施所提供的能力和产能形成互补。

As part of the agreement, Emergent itself has the right to secure manufacturing capacity from the facility in the future, representing offtake potential from US-based innovators. It will also support the growing animal health segment in which a US site is often a key client requirement..

根据协议，Emergent 本身有权在未来获得该工厂的生产能力，这代表了来自美国创新企业的承购潜力。该工厂还将支持不断增长的动物健康领域，在这一领域，美国的生产基地往往是关键的客户需求。

About Syngene

关于Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 5600 scientists offer both skills and the capacity to deliver great science, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation.

Syngene International Ltd.（孟买证券交易所代码：539268，国家证券交易所代码：SYNGENE，ISIN：INE 398R01022）是一家为全球制药、生物技术、营养、动物健康、消费品和特种化学品领域提供综合研究、开发和制造服务的公司。Syngene 拥有超过 5600 名科学家，他们具备技能和能力，能够快速提供卓越的科学成果、可靠的数据安全性和世界级的制造水平，从而加快产品上市时间并降低创新成本。

With.

随着。

2.2 Mn sq. ft of specialized discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including BMS, GSK, Zoetis and Merck KGaA. For more details, visit

220万平方英尺的专业发现、开发和制造设施，Syngene与追求前沿科学的生物技术公司以及包括百时美施贵宝（BMS）、葛兰素史克（GSK）、硕腾（Zoetis）和默克（Merck KGaA）在内的跨国公司合作。欲了解更多信息，请访问

www.syngeneintl.com

For the Company's latest Environmental, Social, and Governance (ESG)report, visit

如需获取公司最新的环境、社会及治理（ESG）报告，请访问

https://esgreport.syngeneintl.com

。

Contact details

联系方式

Investor Contacts

投资者联系方式

Media Contacts

媒体联系人